- Home
- CDIO vs ADXN Comparison
CDIO vs ADXN Comparison
Compare CDIO & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDIO
- ADXN
- Stock Information
- Founded
- CDIO 2017
- ADXN 2002
- Country
- CDIO United States
- ADXN Switzerland
- Employees
- CDIO N/A
- ADXN N/A
- Industry
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- CDIO Health Care
- ADXN Health Care
- Exchange
- CDIO Nasdaq
- ADXN Nasdaq
- Market Cap
- CDIO 7.0M
- ADXN 8.1M
- IPO Year
- CDIO N/A
- ADXN N/A
- Fundamental
- Price
- CDIO $4.77
- ADXN $10.23
- Analyst Decision
- CDIO Buy
- ADXN Strong Buy
- Analyst Count
- CDIO 1
- ADXN 1
- Target Price
- CDIO $60.00
- ADXN $30.00
- AVG Volume (30 Days)
- CDIO 102.5K
- ADXN 1.4K
- Earning Date
- CDIO 05-15-2025
- ADXN 06-17-2025
- Dividend Yield
- CDIO N/A
- ADXN N/A
- EPS Growth
- CDIO N/A
- ADXN N/A
- EPS
- CDIO N/A
- ADXN 0.08
- Revenue
- CDIO $19,902.00
- ADXN $452,495.00
- Revenue This Year
- CDIO $1,434.82
- ADXN $86.57
- Revenue Next Year
- CDIO $4,661.91
- ADXN N/A
- P/E Ratio
- CDIO N/A
- ADXN $0.88
- Revenue Growth
- CDIO N/A
- ADXN N/A
- 52 Week Low
- CDIO $3.40
- ADXN $6.51
- 52 Week High
- CDIO $53.10
- ADXN $13.27
- Technical
- Relative Strength Index (RSI)
- CDIO 39.92
- ADXN 73.57
- Support Level
- CDIO $3.88
- ADXN $8.08
- Resistance Level
- CDIO $5.20
- ADXN $8.20
- Average True Range (ATR)
- CDIO 0.48
- ADXN 0.23
- MACD
- CDIO 0.32
- ADXN 0.11
- Stochastic Oscillator
- CDIO 68.25
- ADXN 71.04
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.